Ambev SA ADR (ABEV)vsPfizer Inc (PFE)
ABEV
Ambev SA ADR
$3.29
+0.30%
CONSUMER DEFENSIVE · Cap: $53.50B
PFE
Pfizer Inc
$25.68
-1.40%
HEALTHCARE · Cap: $150.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Ambev SA ADR generates 39% more annual revenue ($88.21B vs $63.32B). ABEV leads profitability with a 17.7% profit margin vs 11.8%. ABEV appears more attractively valued with a PEG of 2.31. ABEV earns a higher WallStSmart Score of 57/100 (C).
ABEV
Buy57
out of 100
Grade: C
PFE
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+74.4%
Fair Value
$11.91
Current Price
$3.29
$8.62 discount
Margin of Safety
+29.4%
Fair Value
$37.48
Current Price
$25.68
$11.80 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Generating 11.6B in free cash flow
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 26.5%
Strong operational efficiency at 31.6%
Large-cap with strong market position
Reasonable price relative to book value
Generating 2.2B in free cash flow
Areas to Watch
Expensive relative to growth rate
2.2% earnings growth
Revenue declined 0.1%
Weak financial health signals
Expensive relative to growth rate
Earnings declined 10.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABEV
The strongest argument for ABEV centers on Free Cash Flow, Market Cap, P/E Ratio. Profitability is solid with margins at 17.7% and operating margin at 26.5%.
Bull Case : PFE
The strongest argument for PFE centers on Operating Margin, Market Cap, Price/Book.
Bear Case : ABEV
The primary concerns for ABEV are PEG Ratio, EPS Growth, Revenue Growth.
Bear Case : PFE
The primary concerns for PFE are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
ABEV profiles as a declining stock while PFE is a value play — different risk/reward profiles.
PFE carries more volatility with a beta of 0.30 — expect wider price swings.
PFE is growing revenue faster at 5.4% — sustainability is the question.
ABEV generates stronger free cash flow (11.6B), providing more financial flexibility.
Bottom Line
ABEV scores higher overall (57/100 vs 55/100), backed by strong 17.7% margins. PFE offers better value entry with a 29.4% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ambev SA ADR
CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA
Ambev SA produces, distributes and sells beer, draft beer, carbonated soft drinks (CSD), other non-alcoholic beverages, malt and food products in the Americas. The company is headquartered in So Paulo, Brazil.
Pfizer Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.
Visit Website →Compare with Other BEVERAGES - BREWERS Stocks
Want to dig deeper into these stocks?